Loading stock data…
BCRX
$9.19+0.03 (+0.33%)
Market ClosedLast close May 1
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioCryst Pharmaceuticals, Inc. in the Healthcare sector is trading at $9.19. The stock is currently 19% below its 52-week high of $11.31, remaining 16.6% above its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why BCRX maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.19
Potential Upside
222.2%
Whystock Fair Value$29.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$21.40+132.9%
Range$14.00 – $32.00
Fundamentals
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.26B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
7.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.97%
Volume
Today's trading volume
2.27M
Recent News
RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the best drug stocks to buy according to analysts. On April 7, RBC Capital lifted the price target on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to $14 from $13 while maintaining an Outperform rating on the shares. The rating update came as part of a broader research note by the […]
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group.
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets
BioCryst Pharmaceuticals' fair value estimate sits at US$21.30, with the latest update keeping this price target unchanged. Analysts linking this figure to reiterated FY26 revenue guidance, the completed Astria Therapeutics acquisition, and expectations around Orladeyo and pipeline assets are effectively signaling that their core thesis is intact, even as they debate execution risk and timelines. As you read on, you will see how these moving pieces shape the evolving analyst story around...
BioCryst Shares Remain Undervalued, RBC Says
BioCryst Pharmaceuticals (BCRX) remains undervalued even with a recent price increase due to unconf
BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Dominating Today’s Market Action. BioCryst grew its share prices by 7.10 percent on Thursday to close at $9.81 apiece as investors repositioned portfolios following rumors that it is set to be acquired by a large-cap US biopharmaceutical company. The report first broke out on Monday […]